Micah Ostrowski

Micah Ostrowski

Auto-generated profile, based on publicly available information

Micah Ostrowski

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Journal of Kidney Cancer
Verified
Journal Article
Open access
PDF file
MOMicah Ostrowski
Micah Ostrowski
YJYeonjung Jo
Yeonjung Jo
GGGeorges Gebrael
Georges Gebrael
CCChadi Hage Chehade
Chadi Hage Chehade
ZOZeynep Irem Ozay
Zeynep Irem Ozay
USUmang Swami
Umang Swami
Ipilimumab with nivolumab (Ipi + Nivo) and immune checkpoint inhibitors with tyrosine kinase inhibitors (ICI + TKI) are the first-line approved treatments for intermediate- and poor-risk metastatic clear cell renal cell carcinoma (mccRCC); however, they have not been compared head-to-head in prospective trials to guide treatment selection. Thereupon, we sought to compare survival outcomes of patients receiving first-line Ipi + Nivo versus ICI + TKI, using a large, real-world database among patients with intermediate- and poor-risk mccRCC. This retrospective cohort study used a nationwide electronic health record-derived deidentified database, where patients with mccRCC with intermediate- or poor-risk who received first-line Ipi + Nivo or ICI + TKI between 20 June, 2016, and 26 January, 2023, were included. Primary outcomes were real-world time to next therapy (rwTTNT) and real-world overall survival (rwOS), summarized via Kaplan-Meier survival estimates with 95% confidence intervals (CIs) and compared in the context of propensity score (PS) matching weighted analysis. Of the 12,707 patients in the dataset, 1,438 with mccRCC met eligibility and were included. After PS matching weighted analysis, no significant difference in rwOS was noted between both groups (HR 1.01, 95% CI 0.86–1.19; p = 0.91); however, rwTTNT was significantly shorter with Ipi + Nivo than with ICI + TKI (HR 0.78, 95% CI 0.68–0.89; p < 0.001). In this large real-world study, there was evidence that rwOS was comparable, while rwTTNT was superior in patients receiving ICI + TKI compared to those receiving Ipi + Nivo. These real-world data offer important guidance for clinicians in choosing between Ipi + Nivo and ICI + TKI as frontline treatment.

1 April 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
MOMicah Ostrowski
Micah Ostrowski
YJYeonjung Jo
Yeonjung Jo
THTanner Hardy
Tanner Hardy
GGGeorges Gebrael
Georges Gebrael
ASAyana Srivastava
Ayana Srivastava
Umang SwamiUmang Swami
Umang Swami
PURPOSE: The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the recent approvals of lutetium Lu 177 vipivotide tetraxetan and poly (ADP-ribose) polymerase inhibitors, adding new layers of complexity to treatment sequencing. Cabazitaxel is an approved option in patients with disease progression on docetaxel. Real-world data on the effectiveness of cabazitaxel by line of therapy remain limited. To address this gap, we evaluated survival outcomes based on line of therapy in patients with mCRPC receiving single-agent cabazitaxel in a large real-world database. METHODS: This retrospective study used the US-based Flatiron Health electronic health record–derived deidentified database. Patients who were diagnosed with mCRPC and received single-agent cabazitaxel for the first time were eligible and included. Real-world time to next treatment (rwTTNT) and real-world overall survival (rwOS) were calculated from the date patients initiated the first cycle of cabazitaxel. Survival rates were summarized using medians and 95% CI using the Kaplan-Meier method. RESULTS: Among 24,105 patients with metastatic prostate cancer in the data set, 1,315 patients with mCRPC were eligible and included. The median age was 73 years (IQR, 67-78). The majority were non-Hispanic White (62%), treated in community practice (84%), had commercial insurance (81%), and received treatment in fourth line or later (58%). For the overall cohort, the median rwTTNT was 4.7 months (95% CI, 4.4 to 5.0), and the median rwOS was 8.6 months (95% CI, 8.0 to 9.3). The median rwTTNT ranged from 4.2 months to 6.8 months, and rwOS ranged from 6.3 months to 14 months based on the line of therapy. CONCLUSION: In this large, real-world study of patients with mCRPC, cabazitaxel retained its effectiveness regardless of its line of therapy.